Abstract
Introduction
Within 10 years of radical prostatectomy (RP), up to 30% of prostate cancer (PCa) patients will have a rise in prostate-specific antigen (PSA), requiring radiation therapy (RT). However, with current technology, distinction between local and distant recurrent PCa is not possible. This lack of an accurate test constrains the decision whether to offer systemic or local treatment. We hypothesise tests for detecting circulating tumour cells (CTCs) within the blood may assist with clinical decision-making and in this pilot study we investigated whether CTCs could be detected in this patient population using the CellSearch® system.
Materials and methods
Blood samples were collected from PCa patients (n=26) prior to RT and 3 months following completion of RT. Samples were analysed for PSA level via immunoassay and CTC number using the CellSearch® system.
Results
CTCs could be detected in this patient population and following RT CTCs appeared to decrease. However, no association was observed between a higher PSA and an increased number of CTCs pre- or post-RT. Interestingly, patients who failed RT trended toward an increased/unchanged number of CTCs following RT vs. a decreased number in patients with RT response.
Conclusions
Our results demonstrate that CTCs can be detected in early-stage PCa and suggest the possibility that post-treatment reduction in CTC levels may be indicative of RT response. We are currently evaluating CTCs in a larger cohort of patients to validate our preliminary findings and further investigate the prognostic value of CTCs in this patient population.
Similar content being viewed by others
References
Canadian Cancer Statistics, 2010. Canadian Cancer Society, Toronto. Available at: www.cancer.ca
Chalasani V, Iansavichene AE, Lock M, Izawa JI (2009) Salvage radiotherapy following radical prostatectomy. Int J Urol 16:31–36
Ohori M, Goad JR, Wheeler TM et al (1994) Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152:1843–1849
Pound CR, Partin AW, Eisenberger MA, Pearson JD (1997) Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin N Am 24:395–406
Lee AK, D’Amico AV (2005) Utility of prostatespecific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 23:8192–8197
Maier J, Forman J, Tekyi-Mensah S et al (2004) Salvage radiation for a rising PSA following radical prostatectomy. Urol Oncol 22:50–56
Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8:329–340
de Bono JS, Scher HI, Montgomery RB et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309
Mostert B, Sleijfer S, Foekens JA, Gratama JW (2009) Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 35:463–474
Cohen SJ, Punt CJA, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221
Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791
Tombal B, Van Cangh PJ, Loric S, Gala JL (2003) Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate 56:163–170
Allard WJ, Matera J, Miller MC et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897–6904
Davis JW, Nakanishi H, Kumar VS et al (2008) Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol 179:2187–2191
Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035–2041
Allan AL, Keeney M (2010) Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol 2010:426218
Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454
Lilja H, Ulmert D, Vickers AJ (2008) Prostatespecific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8:268–278
Zegarra-moro OL, Schmidt LJ, Huang H, Tindall DJ (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cell Proliferat 62:1008–1013
Yoshimoto M, Cunha IW, Coudry RA et al (2007) FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 97:678–685
Tomlins SA, Mehra R, Rhodes DR et al (2006) TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66:3396–3400
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lowes, L.E., Lock, M., Rodrigues, G. et al. Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy. Clin Transl Oncol 14, 150–156 (2012). https://doi.org/10.1007/s12094-012-0775-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0775-5